VIRX Viracta Therapeutics, Inc.: רווח למניה לשנה מתגלגלת

Viracta Therapeutics (VIRX) develops targeted therapies for lymphomas, minimizing regulatory risks through a global network of trials. Historical EPS YoY TTM dynamics demonstrate the issuer's fundamental condition, with the metric reaching a value of 8.00. Long-term contracts and flexible supply routes ensure stability of supply. However, geopolitical tensions could slow the certification of new drugs due to disruptions in reagent supply chains.
VIRX (Viracta Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Under the Federal Reserve's tight monetary policy, capital protection against volatility becomes the investor's priority. This indicator measures the rate of change in net earnings per share over a rolling year, revealing the issuer's resilience to rising borrowing costs. By analyzing the percentage change in EPS YoY over 12 months, one can assess the efficiency of cost management. For Viracta Therapeutics (VIRX), which is currently in the clinical testing stage, this metric is critical due to the absence of stable cash flow. The trend of this indicator reflects the financial pressure on the company until the moment of drug commercialization.